Orforglipron (LY-3502970) vs Vasopressin
Updated October 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Orforglipron (LY-3502970) and Vasopressin (also searched as Vasopressin vs Orforglipron (LY-3502970)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Orforglipron (LY-3502970) centers on metabolic, while Vasopressin leans toward neuro. On indexed research, Vasopressin is ahead (Orforglipron (LY-3502970): 36 studies, Human clinical; Vasopressin: 42, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Orforglipron (LY-3502970) is strongest for metabolic; Vasopressin for neuro.
- •Evidence: Orforglipron (LY-3502970) Human clinical (36 studies) vs Vasopressin Human clinical (42).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 Agonist | Type 2 Diabetes and Obesity
Vasopressin | Septic shock management
Orforglipron (LY-3502970) vs Vasopressin: side-by-side
| Metric | Orforglipron (LY-3502970) | Vasopressin |
|---|---|---|
| Class | Metabolic | Healing |
| Regulatory status | FDA-approved | FDA-approved |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 36 | 42 |
| Research level | FDA Approved | FDA Approved |
| Strongest effect | Metabolic & appetite | Neuro & mood |
| Healing & recovery | 2.0▲ | 2.0▲ |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 5.0▲ | 3.0 |
| Neuro & mood | 2.0 | 4.0▲ |
| Sleep & circadian | 2.0▲ | 2.0▲ |
| Inflammation & immune | 3.0▲ | 3.0▲ |
| Skin & aesthetics | 3.0▲ | 1.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Orforglipron (LY-3502970) | Vasopressin |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | V1 and V2 receptor agonist |
| Route | Oral | Subcutaneous injection |
| Half-life | — | ~10–20 min |
| Time to peak | — | 30–60 min |
| Duration of action | — | 2–8 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Orforglipron (LY-3502970)?
Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.
Full Orforglipron (LY-3502970) profile, mechanism & studies →What is Vasopressin?
Research peptide discovered via AI researcher. peptide-based therapeutic
Full Vasopressin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~2.0/5 |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | Orforglipron (LY-3502970) | 5.0/5 effect signal |
| Neuro | Vasopressin | 4.0/5 effect signal |
| Sleep | Even | Both ~2.0/5 |
| Inflammation | Even | Both ~3.0/5 |
| Skin | Orforglipron (LY-3502970) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Orforglipron (LY-3502970) and Vasopressin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Orforglipron (LY-3502970) vs Vasopressin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Orforglipron (LY-3502970) has 36 approved studies indexed (Human clinical), and Vasopressin has 42 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Orforglipron (LY-3502970) or Vasopressin better?
It depends on your goal. Orforglipron (LY-3502970) is strongest for metabolic; Vasopressin for neuro. Vasopressin has more indexed studies (42). See the goal-by-goal breakdown above.
Is Orforglipron (LY-3502970) or Vasopressin better for weight loss?
Orforglipron (LY-3502970) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Orforglipron (LY-3502970) or Vasopressin better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, Orforglipron (LY-3502970) or Vasopressin?
Orforglipron (LY-3502970) has 36 approved studies indexed (Human clinical); Vasopressin has 42 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Orforglipron (LY-3502970) and Vasopressin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Orforglipron (LY-3502970) vs Vasopressin?
Orforglipron (LY-3502970): no community-reported effects logged yet. Vasopressin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Orforglipron (LY-3502970) or Vasopressin FDA-approved?
Orforglipron (LY-3502970) is FDA-approved. Vasopressin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Vasopressin better than Orforglipron (LY-3502970)?
For neuro, Vasopressin has the edge; for metabolic, Orforglipron (LY-3502970) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 27, 2026.